Brief: Arcutis Submits SNDA For Zoryve Cream For Treatment Of Plaque Psoriasis In Children
03/09/2025 16:53
Sept 3 (Reuters) - Arcutis Biotherapeutics Inc ARQT.O: ARCUTIS SUBMITS SUPPLEMENTAL NEW DRUG APPLICATION FOR ZORYVE® (ROFLUMILAST) CREAM 0.3% TO EXPAND INDICATION FOR TREATMENT OF PLAQUE PSORIASIS IN CHILDREN AGES 2 TO 5 Source text: ID:nGNX1zr2VW Further company coverage: ARQT.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Arcutis Biotherapeutics
See all newsBrief: Arcutis Biotherapeutics reports inducement grants under Nasdaq listing rule 5635(C)(4
Arcutis Q1 product revenue rises 65% yr/yr, net loss narrows
Brief: Arcutis Announces Promotion Of MAS Matsuda To Executive Vice President And Chief Legal Officer To Support Next Phase Of Growth
Brief: Arcutis Begins Enrolling Phase 1A/1B Study Evaluating Arq-234, A Cd200r Agonist, In Healthy Volunteers And Adults With Atopic Dermatitis
Brief: Arcutis Biotherapeutics Inc Files For Mixed Shelf